Document Detail


Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
MedLine Citation:
PMID:  9130689     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The authors report on the preliminary results of an ongoing phase II trial whereby the combination of the new DNA hypomethylating agent, 5-Aza-deoxycytidine (DAC), plus daunorubicin was given as first-line induction therapy to non-pretreated patients with acute myeloid leukemia (except FAB M3). DAC was given as a 4-h intravenous infusion at the dose of 90 mg/m2 daily from days 1-5, while daunorubicin was administered at the dose of 50 mg/m2 on days 1-3. A maximum of two courses were given to the patients with an interval of 4-6 weeks. Up to now, eight patients were accrued, of those six were evaluable for toxicity and response. The main toxic effects were bone marrow suppression, mucositis, nausea and vomiting, and alopecia. All six patients achieved a complete remission after one (five cases) or two (one case) courses. The trial is open for patient accrual.
Authors:
G Schwartsmann; M S Fernandes; M D Schaan; M Moschen; L M Gerhardt; L Di Leone; B Loitzembauer; L Kalakun
Related Documents :
7471119 - Phase i study of 3-deazauridine in the treatment of adults with solid tumors.
3708609 - Phase i study of triglycidylurazol given on a 5-day i.v. schedule.
21885139 - External beam radiotherapy combined with intraluminal brachytherapy in esophageal carci...
21824889 - Neurocytomas: long-term experience of a single institution.
934029 - Mitomycin c in large infrequent doses in breast cancer.
21868559 - Gene polymorphisms mthfrc677t and mtra2756g as predictive factors in adjuvant chemother...
16821609 - Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomita...
22885989 - Patients with diffuse large b cell lymphoma in partial response or stable disease after...
2557309 - Twenty year experience with radiation therapy for temporal bone chemodectomas.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article    
Journal Detail:
Title:  Leukemia     Volume:  11 Suppl 1     ISSN:  0887-6924     ISO Abbreviation:  Leukemia     Publication Date:  1997 Mar 
Date Detail:
Created Date:  1997-05-22     Completed Date:  1997-05-22     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8704895     Medline TA:  Leukemia     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S28-31     Citation Subset:  IM    
Affiliation:
South-American Office for Anticancer Drug Development (SOAD), Hospital de Clinicas de Porto Alegre, RS, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antimetabolites, Antineoplastic / administration & dosage,  therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Azacitidine / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Bone Marrow / drug effects,  pathology
Daunorubicin / administration & dosage
Drug Administration Schedule
Female
Humans
Immunophenotyping
Infusions, Intravenous
Karyotyping
Leukemia, Myeloid, Acute / drug therapy*,  genetics,  immunology,  pathology
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 20830-81-3/Daunorubicin; 320-67-2/Azacitidine; 776B62CQ27/decitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine ...
Next Document:  Studies of decitabine with allogeneic progenitor cell transplantation.